Your cannabis business is running, licenses are in hand, and every month you're deciding where capital goes. Do you expand the grow? Add a processing line? Bring distribution in-house? Or do you put money into the wider industry instead?
Those aren't passive investor questions. They're the calls real operators make when the market is consolidating and every dollar has to work harder. This guide covers both sides: outside investors looking for cannabis exposure, and licensed operators deciding where growth capital goes next.
How to Invest in Cannabis: The Short Answer
You can invest in cannabis five ways: buy shares of cannabis companies, buy a cannabis ETF, buy a cannabis-focused REIT, invest in ancillary businesses that serve the industry, or put money into private cannabis companies. Most people start with an ETF or a few large multi-state operators, then add ancillary or private deals once they understand the risks.
A cannabis investment is any position whose returns depend on the legal cannabis market, whether the company touches the plant or just sells to the people who do. Here's how the five options compare at a glance:
- Cannabis stocks: direct exposure to U.S. multi-state operators (MSOs) or Canadian producers. Highest upside, highest volatility.
- Cannabis ETFs: a basket of companies in one ticker. Less work, less single-company risk.
- Cannabis REITs: landlords to licensed operators. Income from rent, tied to tenant health.
- Ancillary companies: software, testing, packaging, and services. No plant-touching license risk.
- Private investment: equity or debt in private operators and startups. Illiquid and hard to value.
Not financial advice: nothing in this article is financial, legal, or investment advice. Talk to a licensed financial advisor and a cannabis-specialized CPA before you invest.
Is Cannabis a Good Investment in 2026?
The short answer: it's a real market with real tailwinds, but it isn't the growth story it was in 2019. Here's where things stand as of October 2026.
Sales are flat, not booming. State-licensed cannabis sales hit $29.1 billion in 2025, down slightly from $30.1 billion in 2024, according to the Vangst and Whitney Economics jobs report summarized by NORML in June 2026. The authors blame lower prices from oversupply, not weaker demand, and project sales above $43 billion by 2030.
Rescheduling is half done. On April 23, 2026, the Justice Department issued a final order moving FDA-approved marijuana products and state-licensed medical marijuana to Schedule III, according to the DEA's rescheduling page. Adult-use marijuana stays in Schedule I. A separate DEA hearing on rescheduling all marijuana opened June 29, 2026, then an administrative law judge stayed the proceedings on September 29 to weigh a new GAO report. The government's response was due October 13. There's no final date for adult-use rescheduling yet (checked Oct 2026).
280E relief depends on your license. Medical-only licensees are no longer subject to IRS Code 280E, the rule that blocks normal business deductions for Schedule I and II traffickers. Adult-use-only operators still are, and the treatment of dispensaries selling both medical and adult-use product is still unclear, per Foley & Lardner's analysis of the order. IRS guidance is still pending.
Banking is still stuck. The SAFE Banking Act of 2026 was filed in the Senate on June 24 and in the House on June 25, per The National Law Review. It hasn't passed either chamber. Earlier versions passed the House seven times and died in the Senate every time.
Capital markets are opening a crack. Trulieve began trading on the New York Stock Exchange under TRLV on June 10, 2026, the first U.S. MSO to list there. Most MSOs still trade over the counter or on the Canadian Securities Exchange.
So is it a good investment? For disciplined investors who price risk honestly, it can be. For anyone counting on federal legalization to bail out a weak company, it's a bad bet.
5 Ways to Invest in Cannabis
Each option carries a different mix of upside, liquidity, and risk. Here's what you're actually buying with each one.
1. Cannabis Stocks (MSOs and LPs)
U.S. multi-state operators like Green Thumb Industries (GTBIF), Trulieve (TRLV), and Curaleaf (CURLF) are the most direct equity plays on the U.S. market. To buy them, you need a brokerage that allows OTC or Canadian-listed trades, since most MSOs still aren't on a major U.S. exchange. Trulieve's NYSE listing is the exception so far.
What to look for: positive free cash flow, manageable debt, and disciplined expansion. The MSOs that survived the 2022 to 2023 downturn did it by cutting costs and focusing on profitable markets, not by chasing license counts.
Canadian licensed producers (LPs) trade on NASDAQ and the NYSE but have limited U.S. exposure and a long history of profitability problems. They're a different risk profile than U.S. MSOs.
How to Read an MSO's Capex Guidance
Capital expenditure (capex) guidance tells you where management plans to spend cash on stores, cultivation, and systems. Compare it to free cash flow: if capex is rising faster than cash from operations, the company is funding growth with debt or dilution.
Here's a real example. In its Q2 2026 earnings presentation, Trulieve guided to 2026 capex of up to $95 million, up from $85 million, for investments in growth markets. The questions to ask: which markets, how fast those stores or facilities pay back, and whether the spend still makes sense if adult-use rescheduling stalls.
2. Cannabis ETFs
Cannabis ETFs spread your exposure across many companies instead of one operator. The AdvisorShares Pure US Cannabis ETF (MSOS) focuses on U.S. operators. The Amplify Alternative Harvest ETF (MJ) holds a broader global mix.
ETFs suit investors who want cannabis exposure without digging into individual financials. The tradeoff: you hold the weaker companies right alongside the stronger ones. Check each fund's holdings and how much of it is U.S. MSOs versus Canadian LPs or tobacco and pharma names.
3. Cannabis REITs
Innovative Industrial Properties (IIPR) is the best-known cannabis REIT. It buys real estate from licensed operators and leases it back to them, paying out rental income as dividends. Your return depends on tenants paying rent, not on them being wildly profitable.
The risk: when tenants hit financial trouble or default, the REIT feels it fast. Read the tenant list and watch for concentration in a few operators.
4. Ancillary Companies
Some of the strongest risk-adjusted cannabis investments don't touch the plant. Ancillary companies sell software, packaging, testing equipment, lighting, and business services to the industry. They benefit from market growth without carrying plant-touching license risk.
Distru, a Cannabis AI ERP with a built-in B2B wholesale marketplace, sits in this category. The platform has processed more than $10 billion in wholesale sales for 440+ customers in 30+ states. That's a measure of real operating volume inside the legal market.
If you're after infrastructure plays, software and compliance technology are the picks-and-shovels bet in cannabis.
5. Private Investment
Private cannabis companies can return more if they win, but they're illiquid, hard to value, and fail more often. This bucket includes direct equity in licensed operators, cannabis-focused venture funds, and angel deals in cannabis startups.
If you go this route, do real due diligence: audited financials, compliance history, license status, and a hard look at the management team's track record.
Key Risks Every Cannabis Investor Needs to Understand
The biggest risks in cannabis are regulatory timing, taxes, prices, and the cost of capital. Here's how each one shows up in returns.
Federal Regulatory Uncertainty
Medical marijuana is in Schedule III. Adult-use isn't, and the hearing that could move it is paused. Rules can shift with a court order, a new report, or a change in administration. Don't price in relief until it's final, and don't assume a timeline anyone gives you.
280E Tax Burden (Still Active for Adult-Use)
Under IRS Code 280E, adult-use operators still can't deduct normal business expenses beyond cost of goods sold. An operator with $5 million in revenue and $4 million in operating costs can't write off most of those costs the way a normal business would. Effective federal tax rates for affected operators are often cited at 40% to 70%. That crushes cash flow and limits reinvestment. Medical-only operators now get relief, which makes license mix a real valuation question.
Pricing Compression
In oversupplied markets like California and Michigan, wholesale flower prices have dropped sharply over the last few years. That's the main reason 2025 sales dipped even as demand held. Lower prices squeeze cultivators first, then push pressure down the whole supply chain. Operators who can't cut production costs fast enough get squeezed out.
Capital Constraints
Cannabis companies still have limited access to traditional bank loans. Most raise money through private equity, high-interest debt, or sale-leaseback deals. That makes capital more expensive than in most industries, and it matters a lot when you're trying to scale.
Market Saturation in Early States
Colorado, California, and Oregon are mature and crowded. Returns on new entries there are thin. Newer markets like New York, Ohio, and Minnesota still have supply catching up to demand, but they carry their own risks: regulatory delays, thin distribution, and uncertain demand curves.
How Operators Should Think About Investment
If you're already licensed, investing usually means putting capital into your own operation first. The same discipline applies: clear ROI, realistic timelines, and honest costs.
You're not choosing between MSOS and IIPR. You're deciding whether to put $500K into a new extraction line, add a second cultivation facility, bring distribution in-house, or hire a team to open a new state.
Operators who scale well tend to have two things in common. They know their numbers cold, and they invest in operational infrastructure before capacity. The ones who stumble do it in reverse: they expand production before they have the systems to manage it.
Operational infrastructure includes:
- Seed-to-sale compliance tracking
- Inventory and warehouse management
- Cost accounting that shows true COGS by SKU
- Order management and invoicing
- Financial reporting that connects to your accounting software
Hours spent reconciling Metrc transfers, re-entering invoices, or chasing batch records don't show up as a line on your P&L. They still cost you margin. That's why 440+ customers in 30+ states run on Distru's cannabis ERP to keep inventory, costing, and compliance in one system.
If you want to be investment-ready, whether you're raising capital, pursuing an acquisition, or planning an exit, you need clean books and auditable operations. Lenders and buyers will ask for COGS by SKU, inventory accuracy, and wholesale revenue by account. If your B2B sales still run on texts and spreadsheets, our guide to the wholesale marijuana market is a good place to start.
Cannabis Investment Due Diligence Checklist
Whether you're looking at a public MSO or a private operator, check these seven things before you put money in.
- License status and compliance history. Violations, license restrictions, or pending regulatory actions are red flags.
- License mix. How much revenue is medical versus adult-use? That now changes the 280E math.
- Revenue trend vs. margin trend. Revenue growth with shrinking margins is a warning sign.
- Debt structure. What maturities are coming due, and how will they be refinanced?
- Cash flow from operations. Is the business generating cash or burning it?
- Market concentration. How dependent is the company on one state or one license type?
- Operational systems. For private operators especially, do they run on systems that produce auditable data, or on spreadsheets?
For broader context, the Cannabis Business Times 2026 industry outlook is worth a read.
What the Consolidation Wave Means for Investors
Consolidation means weaker operators are selling or shutting down, and stronger ones are buying distressed assets cheap. It's a normal maturation cycle. Beer, telecom, and retail pharmacy all went through it.
For investors, that cuts both ways. MSOs buying distressed assets can build market share cheaply, but integration is hard. Owning a license in a new state isn't the same as running profitably there. Watch how acquisitions actually perform a year later.
For operators, it's a threat and an opportunity. If you're lean and profitable, you're an acquisition target, possibly at a good valuation. If you're running thin margins with compliance issues, you're at risk of landing on the wrong side of a deal. Operators with clean systems and data walk into those negotiations in a much stronger spot.
The Bottom Line
Cannabis is a $29 billion state-legal market with real tailwinds: medical rescheduling is done, 280E relief has started for medical operators, and the first MSO is on the NYSE. But adult-use rescheduling is paused, banking reform hasn't passed, and prices are still falling in mature states.
The investors and operators who do well stay disciplined: clean financials, efficient operations, and honest underwriting of risk. If you're an outside investor, focus on companies that show you cash flow, not just revenue growth. If you're an operator, build the infrastructure that makes your current business defensible before you add capacity.
Want to see how operational infrastructure drives ROI for licensed operators? Schedule a demo with Distru and see how 440+ customers across 30+ states keep their books clean and their inventory accurate.
This article is for informational purposes only and doesn't constitute financial, legal, or investment advice. Consult a licensed financial advisor and a cannabis-specialized CPA before making investment decisions. Adult-use cannabis remains a Schedule I controlled substance under federal law, and investing in cannabis businesses carries significant legal and financial risk. Regulatory status checked October 2026.
